"To date a significant number of clinical trials involving isoflavonoids have been undertaken. None of these trials have demonstrated consistent efficacy. For example, Idronoxil has held an IND from the US FDA since about 2000 in both oral and intravenous dosage formulations and in that form has undergone over 12 Phase 1 , Phase 2 and Phase 3 clinical studies in over 300 patients with late-stage cancers. Instances of clinical response (complete response, partial response, stable disease) have been observed, but neither dosage formulation has delivered a consistent, clinically meaningful anti-cancer effect.............
Given the amount of effort over the last 25 years that has gone into the clinical development of isoflavonoids as human therapeutics based on their potent anti-tumour effects in pre-clinical studies, it is remarkable that no isoflavonoid has come to market, perhaps pointing to a general acceptance of the research community that the clinical efficacy of isoflavonoids is limited by the inherent hydrophobicity of the molecules."
https://patentscope.wipo.int/search...queryString=FP:(noxopharm)&tab=PCTDescription
I suspect todays release of data will show pretty much the same as it has always shown ie "Instances of clinical response (complete response, partial response, stable disease) have been observed" all very promising and that will be enough to warranty the phase two trials as it did 12 or so years ago. If I am wrong feel free to gloat and abuse as much as you like.
The above quotes are from NOXOPHARM documents, straight out the horse mouth last year.
Add to My Watchlist
What is My Watchlist?
